Claims:

- 1. A multi-dosage liquid pharmaceutical formulation of human growth hormone consisting essentially of human growth hormone at a concentration of from about 5 mg/ml to about 100 mg / ml, glycine, a buffer, a non-ionic surfactant, and a preservative, said pharmaceutical formulation having a tonicity of from about 100 to about 500 mosm/kg and having a pH of from about 6.1 to about 6.3.
- 2. The pharmaceutical formulation according to claim 1, wherein the concentration of human growth hormone is from about 6 mg/ml to about 14 mg/ml.
- 3. The pharmaceutical formulation according to claim 2, wherein the concentration of human growth hormone is about 6.67 mg/ml.
- 4. The pharmaceutical formulation according to claim 1, wherein the concentration of glycine is from about 5 mg/ml to about 75 mg/ml.
- 5. The pharmaceutical formulation according to claim 1, wherein the concentration of glycine is about 15 mg/ml.
- 6. The pharmaceutical formulation according to claim 1, said pharmaceutical composition being substantially isotonic.
- 7. The pharmaceutical formulation according to claim 1, wherein the buffer is selected from the group consisting of a phosphate buffer, a citrate buffer, an acetate buffer and a formate buffer.
- 8. The pharmaceutical formulation according to claim 6, wherein the buffer is a phosphate buffer.
- 9. The pharmaceutical formulation according to claim 1, wherein the buffer has a concentration of from about 5 mM to about 100 mM.

- 10. The pharmaceutical formulation according to claim 1, wherein the buffer has a concentration of about 10 mM.
- 11. The pharmaceutical formulation according to claim 1, wherein the buffer is a phosphate buffer having a concentration of about 10 mM.
- 12. The pharmaceutical formulation according to claim 1, wherein the non-ionic surfactant is selected from the group consisting of a poloxamer and a polysorbate.
- 13. The pharmaceutical formulation according to claim 1, wherein the non-ionic surfactant is a poloxamer.
- 14. The pharmaceutical formulation according to claim 1, wherein the non-ionic surfactant is poloxamer 188.
- 15. The pharmaceutical formulation according to claim 1, wherein the non-ionic surfactant is present at a concentration of from about 0.05 to about 4 mg/ml.
- 16. The pharmaceutical composition according to claim 1, wherein the non-ionic surfactant is present at a concentration of about 2 mg/ml.
- 17. The pharmaceutical composition according to claim 1, wherein the non-ionic surfactant is poloxamer 188 being present at a concentration of about 2 mg/ml.
- 18. The pharmaceutical formulation according to claim 1, wherein the preservative is selected from the group consisting of benzyl alcohol, meta-cresol, methyl paraben, propyl paraben, phenol, benzalkonium chloride, benzethonium chloride, chlorobutanol, 2-phenoxyethanol, phenyl mercuric nitrate and thimerosal.
- 19. The pharmaceutical formulation according to claim 1, wherein the preservative is benzyl alcohol.
- 20. The pharmaceutical formulation according to claim 1, wherein the preservative is benzyl alcohol being present at a concentration of from about 7 mg/ml to about 12 mg/ml.

PCT/EP2003/007346

and having a pH of 6.2.

- 21. The pharmaceutical formulation according to claim 1, said pharmaceutical composition having a pH of about 6.2.
- 22. The pharmaceutical composition according to claim 1, essentially consisting of 6.67 mg/ml human growth hormone,
 15 mg/ml glycine,
 10 mM sodium phosphate buffer,
 2 mg/ml poloxamer 188,
 9 mg/ml benzyl alcohol,
- 23. A kit comprising an injection device and a separate container containing a multi-dosage liquid formulation of human growth hormone according to claim 1.